Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Wolff, M. Elizabeth, Hale Hammond, K. Allison, Brittany Harvey, P. Mangu, J. Bartlett, M. Bilous, I. Ellis, P. Fitzgibbons, W. Hanna, R. Jenkins, M. Press, P. Spears, G. Vance, G. Viale, L. McShane, M. Dowsett (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 20
G. Sanders, P. Neumann, A. Basu, D. Brock, D. Feeny, M. Krahn, K. Kuntz, D. Meltzer, D. Owens, L. Prosser, J. Salomon, M. Sculpher, T. Trikalinos, L. Russell, J. Siegel, T. Ganiats (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.JAMA, 316 10
G. Torrance (1986)
Measurement of health state utilities for economic appraisal.Journal of health economics, 5 1
Shanly Seferina, B. Ramaekers, M. Boer, M. Dercksen, F. Berkmortel, R. Kampen, A. Wouw, A. Voogd, Vivianne Heijnen, M. Joore (2017)
Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer ConsortiumOncotarget, 8
P. Blank, M. Schwenkglenks, H. Moch, T. Szucs (2010)
Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategiesBreast Cancer Research and Treatment, 124
Nosaibah Hariri, A. Roma, F. Hasteh, V. Walavalkar, O. Fadare (2017)
Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.Annals of diagnostic pathology, 31
L. Garrison, J. Babigumira, A. Masaquel, B. Wang, D. Lalla, M. Brammer (2015)
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 4
D. English, D. Roque, A. Santin (2013)
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic MalignanciesMolecular Diagnosis & Therapy, 17
L. Garrison, D. Lubeck, D. Lalla, V. Paton, A. Dueck, E. Perez (2007)
Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancerCancer, 110
L. Garrison, D. Lalla, M. Brammer, J. Babigumira, B. Wang, E. Perez (2013)
Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 statusCancer, 119
R. Siegel, K. Miller, A. Jemal (2019)
Cancer statistics, 2019CA: A Cancer Journal for Clinicians, 69
M. Rushton, Christopher Johnson, Susan Dent (2017)
Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.Current oncology, 24 3
Vibeke Bertelsen, E. Stang (2014)
The Mysterious Ways of ErbB2/HER2 TraffickingMembranes, 4
(2013)
patients for HER 2 status
G. Tyree, R. Sarkar, B. Bellows, R. Ellis, J. Atkinson, T. Marcotte, M. Wallace, I. Grant, Yuyan Shi, James Murphy, D. Grelotti (2019)
A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic PainCannabis and Cannabinoid Research, 4
P. Neumann, Joshua Cohen, M. Weinstein (2014)
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.The New England journal of medicine, 371 9
R. Barish, E. Gates, A. Barac (2019)
Trastuzumab-Induced Cardiomyopathy.Cardiology clinics, 37 4
James Solomon, M. Dell'aquila, O. Fadare, F. Hasteh (2017)
Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ HybridizationAmerican Journal of Clinical Pathology, 147
N. Dendukuri, K. Khetani, M. McIsaac, J. Brophy (2007)
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisCanadian Medical Association Journal, 176
A. Feldman, B. Lorell, S. Reis (2000)
Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.Circulation, 102 3
S. Ven, V. Smit, T. Dekker, J. Nortier, J. Kroep (2010)
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer treatment reviews, 37 6
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana‐Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, Michael Green, C. Ward, K. Mayne, J. Extra (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 19
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
The American Society of Clinical Oncology and the College of American Pathologists recommend that human epidermal growth factor receptor 2 (HER2)/neu status be determined for all invasive breast cancers. Although the most commonly used modalities to determine HER2/neu status, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), generally give concordant results, a small but consistent discordance rate between them has been demonstrated in prior studies. Most institutions in the United States use a “reflex testing strategy” for determining HER2/neu status. In a reflex testing strategy, cancers are screened with IHC, and FISH is reflexively performed only if the IHC results are classified as equivocal. Other institutions perform both tests on all cancers to maximize diagnostic accuracy (dual testing strategy). The cost-effectiveness of dual testing and reflex testing strategies are comparatively assessed herein. A decision analysis model was established comparing these 2 testing strategies. Model probabilities were obtained from an institutional invasive breast cancer cohort. Quality-adjusted life-years (QALYs) and cost estimates were extracted from published literature. All costs were converted to 2018 US$ values using the consumer price index. One-way sensitivity analysis was performed, as well as probabilistic sensitivity analyses with acceptability curves. A total of 1247 consecutive invasive breast cancer specimens were tested with a dual strategy. By IHC, 65%, 28%, and 10% were negative, equivocal, and positive, respectively. By FISH, 87% and 13% were HER2/neu-negative and HER2/neu-positive, respectively. Six patients whose cancers were IHC-positive (3+) were found to be FISH-negative. These 6 represented 5% of the 119 cases with HER2/neu 3+ scores and 0.55% of the 1082 cases with HER2/neu-negative results by FISH. Sixteen (2%) of 809 cases with a negative IHC result were ultimately classified as HER2/neu-amplified by FISH. These 16 cases constituted 10% of all cases that were ultimately classified as HER2/neu-amplified by FISH. Overall, a reflex testing strategy was found to be less costly than a dual testing strategy ($44,470.99 vs. $45,908.86, respectively), but was also less effective (10.28 vs. 10.30 QALYs). The incremental cost-effectiveness ratio was $70,051.55/QALY. In conclusion, in this single institutional cohort of breast cancers, a dual testing strategy to determine HER2/neu status was found to be more cost-effective than a reflex testing strategy.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 18, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.